Prevnar 13 is a 13-valent pneumococcal conjugate vaccine (PCV) manufactured by Wyeth (Pfizer) pharmaceuticals, containing Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. Prevnar 13 does not protect against infection and disease caused by Streptococcus pneumoniae strains not present in the vaccine.
Prevnar 13 is approved for the following uses:
- In children between the ages of six weeks and five years of age for the prevention of invasive disease and otitis media;
- In children and teenagers between the ages of six and seventeen years of age for the prevention of invasive disease;
- In adults eighteen years of age and older for the prevention of pneumonia and invasive disease.
Prevnar 13 is a 13-valent Pneumococcal Conjugate Vaccine containing Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, each individually linked to non-toxic diphtheria CRM197 protein. Serotypes are each grown in a soy peptone broth and each polysaccharide is purified. Each polysaccharide is then chemically activated to make saccharide and linked to the Diphtheria CRM197 protein to form the glycoconjugate. CRM197, a nontoxic variant of diphtheria toxin, is isolated from cultures of Corynebacterium diphtheria strain C7 which has been grown in a yeast extract and casamino acids based medium or in a chemically-defined medium. CRM197 and each glycoconjugate is then purified and the individual glycoconjugates are joined to make Prevnar 13. Each 0.5ml dose of Prevnar 13 contains approximately 2.2 μg of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, 4.4 μg of 6B saccharides, 34 μg CRM197 carrier protein, 295 μg succinate buffer, 100 μg polysorbate 80, and 125 μg aluminum as aluminum phosphate adjuvant.
